company background image
PRPO logo

Precipio NasdaqCM:PRPO Stock Report

Last Price

US$5.81

Market Cap

US$8.6m

7D

1.0%

1Y

-28.1%

Updated

17 Jun, 2024

Data

Company Financials

PRPO Stock Overview

A healthcare solutions company, provides diagnostic products, reagents, and services in the United States.

PRPO fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Precipio, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Precipio
Historical stock prices
Current Share PriceUS$5.81
52 Week HighUS$8.99
52 Week LowUS$4.75
Beta1.27
1 Month Change-7.63%
3 Month Change-7.04%
1 Year Change-28.09%
3 Year Change-92.23%
5 Year Change-89.98%
Change since IPO-99.78%

Recent News & Updates

Here's Why Shareholders May Want To Be Cautious With Increasing Precipio, Inc.'s (NASDAQ:PRPO) CEO Pay Packet

Jun 07
Here's Why Shareholders May Want To Be Cautious With Increasing Precipio, Inc.'s (NASDAQ:PRPO) CEO Pay Packet

Investors Holding Back On Precipio, Inc. (NASDAQ:PRPO)

Mar 29
Investors Holding Back On Precipio, Inc. (NASDAQ:PRPO)

Recent updates

Here's Why Shareholders May Want To Be Cautious With Increasing Precipio, Inc.'s (NASDAQ:PRPO) CEO Pay Packet

Jun 07
Here's Why Shareholders May Want To Be Cautious With Increasing Precipio, Inc.'s (NASDAQ:PRPO) CEO Pay Packet

Investors Holding Back On Precipio, Inc. (NASDAQ:PRPO)

Mar 29
Investors Holding Back On Precipio, Inc. (NASDAQ:PRPO)

Precipio, Inc.'s (NASDAQ:PRPO) Subdued P/S Might Signal An Opportunity

Aug 29
Precipio, Inc.'s (NASDAQ:PRPO) Subdued P/S Might Signal An Opportunity

Precipio to distribute HemeScreen through Fisher Healthcare channel

Jul 20

Precipio terminates its equity line with Lincoln Park

Jun 15

We Think Some Shareholders May Hesitate To Increase Precipio, Inc.'s (NASDAQ:PRPO) CEO Compensation

Jun 12
We Think Some Shareholders May Hesitate To Increase Precipio, Inc.'s (NASDAQ:PRPO) CEO Compensation

Precipio shares surge on HemeScreen Anemia Panel launch

Jun 08

Precipio shares surge on launching hemescreen panel for Acute Myeloid Leukemia

May 10

Precipio: COVID-19 Testing At Amazon Is An Impressive Yet Transitory Fluke

May 05

Precipio shares jump on launching its rapid COVID-19 antibody test on Amazon platform

May 03

Shareholder Returns

PRPOUS HealthcareUS Market
7D1.0%-0.7%1.6%
1Y-28.1%5.5%21.5%

Return vs Industry: PRPO underperformed the US Healthcare industry which returned 6.1% over the past year.

Return vs Market: PRPO underperformed the US Market which returned 20.8% over the past year.

Price Volatility

Is PRPO's price volatile compared to industry and market?
PRPO volatility
PRPO Average Weekly Movement6.9%
Healthcare Industry Average Movement6.5%
Market Average Movement5.7%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.9%

Stable Share Price: PRPO has not had significant price volatility in the past 3 months.

Volatility Over Time: PRPO's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a54Ilan Danieliwww.precipiodx.com

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels.

Precipio, Inc. Fundamentals Summary

How do Precipio's earnings and revenue compare to its market cap?
PRPO fundamental statistics
Market capUS$8.58m
Earnings (TTM)-US$4.90m
Revenue (TTM)US$15.81m

0.5x

P/S Ratio

-1.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PRPO income statement (TTM)
RevenueUS$15.81m
Cost of RevenueUS$9.62m
Gross ProfitUS$6.19m
Other ExpensesUS$11.09m
Earnings-US$4.90m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-3.34
Gross Margin39.14%
Net Profit Margin-31.00%
Debt/Equity Ratio1.8%

How did PRPO perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.